In Tuesday’s plenary session, investigators, including Joshua Baker, MD, MSCE, presented new data on a lifestyle intervention trial for rheumatoid arthritis, the first head-to-head trial looking at a primary joint endpoint in psoriatic arthritis, longitudinal risk stratification in pulmonary sarcoidosis, disease prediction models, infliximab biosimilar…
Speakers, including Arinola Dada, MD, FACR, outlined strategies for launching and sustaining clinical trials. They discussed how to gain experience to be ready to be a site leader, what it means to work with a site management organization, and more.
Lupus researcher Edith Williams, PhD, and two patient advocates, both of whom live with lupus, will explore how doctors, researchers, and advocates can improve patient-clinician communication in this year’s Daltroy Lecture.
Michael Weintraub, MD, and Veena K. Ranganath, MD, MS, RhMSUS, will discuss the evolving landscape of glucagon-like peptide-1 receptor agonists and current evidence for the use of this kind of incretin therapy in rheumatologic diseases.
Experts will provide an overview of the immunobiology of cellular therapies for rheumatic diseases, examine which diseases might be most responsive to these therapies, share results from recent clinical trials, and debate the correct pace for the widespread use of cellular therapy in rheumatology.